Literature DB >> 21989347

Diagnosis of serous tubal intraepithelial carcinoma based on morphologic and immunohistochemical features: a reproducibility study.

Kala Visvanathan1, Russell Vang, Patricia Shaw, Amy Gross, Robert Soslow, Vinita Parkash, Ie-Ming Shih, Robert J Kurman.   

Abstract

There is compelling evidence that serous tubal intraepithelial carcinoma (STIC) is a precursor of high-grade serous ovarian carcinoma. Large-scale studies are now required to determine its biological significance and clinical implication. Before conducting these studies, a reproducible classification for STIC is needed, and that is the goal of this study. This study involved 6 gynecologic pathologists from 4 academic institutions and 3 independent rounds of review. In round 1, sixty-seven lesions ranging from normal, atypical, to STICs were classified by 5 pathologists on the basis of predetermined morphologic criteria. Interobserver agreement for the diagnosis of STIC versus not STIC was fair [κ = 0.39; 95% confidence interval (CI) 0.26, 0.52], and intraobserver reproducibility ranged from fair to moderate on the basis of percentage agreement and κ. Round 2 involved testing revised criteria that incorporated morphology and immunohistochemistry (IHC) for p53 protein expression and Ki-67 labeling in 10 sets by 3 of the pathologists. The result was an improvement in interobserver agreement for the classification of STIC (κ = 0.62; 95% CI 0.18, 1.00). An algorithm was then created combining morphology and IHC for p53 and Ki-67, and reproducibility was assessed as part of round 3. In 37 lesions reviewed by 6 pathologists, substantial agreement for STIC versus no STIC was observed (κ = 0.73; 95% CI 0.58, 0.86). In conclusion, we have developed reproducible criteria for the diagnosis of STIC that incorporate morphologic and IHC markers for p53 and Ki-67. The algorithm we propose is expected to help standardize the classification of STIC for future studies.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21989347      PMCID: PMC4612640          DOI: 10.1097/PAS.0b013e31822f58bc

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  16 in total

1.  The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome.

Authors:  Fabiola Medeiros; Michael G Muto; Yonghee Lee; Julia A Elvin; Michael J Callahan; Colleen Feltmate; Judy E Garber; Daniel W Cramer; Christopher P Crum
Journal:  Am J Surg Pathol       Date:  2006-02       Impact factor: 6.394

2.  The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory.

Authors:  Robert J Kurman; Ie-Ming Shih
Journal:  Am J Surg Pathol       Date:  2010-03       Impact factor: 6.394

3.  Prognostic significance of cell cycle proteins and genomic instability in borderline, early and advanced stage ovarian carcinomas.

Authors:  H. Blegen; N. Einhorn; K. Sjövall; A. Roschke; B. M. Ghadimi; L. M. McShane; B. Nilsson; K. Shah; T. Ried; G. Auer
Journal:  Int J Gynecol Cancer       Date:  2000-11       Impact factor: 3.437

4.  Serous tubal intraepithelial carcinoma: diagnostic reproducibility and its implications.

Authors:  Joseph W Carlson; Elke A Jarboe; David Kindelberger; Marisa R Nucci; Michelle S Hirsch; Christopher P Crum
Journal:  Int J Gynecol Pathol       Date:  2010-07       Impact factor: 2.762

5.  Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis.

Authors:  Anna Yemelyanova; Russell Vang; Malti Kshirsagar; Dan Lu; Morgan A Marks; Ie Ming Shih; Robert J Kurman
Journal:  Mod Pathol       Date:  2011-05-06       Impact factor: 7.842

6.  Serous carcinogenesis in the fallopian tube: a descriptive classification.

Authors:  Elke Jarboe; Ann Folkins; Marisa R Nucci; David Kindelberger; Ronny Drapkin; Alexander Miron; Yonghee Lee; Christopher P Crum
Journal:  Int J Gynecol Pathol       Date:  2008-01       Impact factor: 2.762

7.  Serous tubal intraepithelial carcinoma upregulates markers associated with high-grade serous carcinomas including Rsf-1 (HBXAP), cyclin E and fatty acid synthase.

Authors:  Ann Smith Sehdev; Robert J Kurman; Elisabetta Kuhn; Ie-Ming Shih
Journal:  Mod Pathol       Date:  2010-03-12       Impact factor: 7.842

8.  HMGA2: a potential biomarker complement to P53 for detection of early-stage high-grade papillary serous carcinoma in fallopian tubes.

Authors:  Jian-Jun Wei; Jingjing Wu; Chunyan Luan; Anjana Yeldandi; Peng Lee; Pacita Keh; Jinsong Liu
Journal:  Am J Surg Pathol       Date:  2010-01       Impact factor: 6.394

9.  Low-molecular weight forms of cyclin E differentiate ovarian carcinoma from cells of mesothelial origin and are associated with poor survival in ovarian carcinoma.

Authors:  Ben Davidson; Martina Skrede; Ilvars Silins; Ie-Ming Shih; Claes G Trope; Vivi Ann Flørenes
Journal:  Cancer       Date:  2007-09-15       Impact factor: 6.860

Review 10.  STICS, SCOUTs and p53 signatures; a new language for pelvic serous carcinogenesis.

Authors:  Karishma Mehra; Mitra Mehrad; Geng Ning; Ronny Drapkin; Frank D McKeon; Wa Xian; Christopher P Crum
Journal:  Front Biosci (Elite Ed)       Date:  2011-01-01
View more
  49 in total

Review 1.  It's Totally Tubular....Riding The New Wave of Ovarian Cancer Research.

Authors:  Ruth Perets; Ronny Drapkin
Journal:  Cancer Res       Date:  2015-12-15       Impact factor: 12.701

2.  The diagnostic and biological implications of laminin expression in serous tubal intraepithelial carcinoma.

Authors:  Elisabetta Kuhn; Robert J Kurman; Robert A Soslow; Guangming Han; Ann Smith Sehdev; Patrick J Morin; Tian-Li Wang; Ie-Ming Shih
Journal:  Am J Surg Pathol       Date:  2012-12       Impact factor: 6.394

3.  Identical TP53 mutations in pelvic carcinosarcomas and associated serous tubal intraepithelial carcinomas provide evidence of their clonal relationship.

Authors:  Laura Ardighieri; Luigi Mori; Sara Conzadori; Mattia Bugatti; Marcella Falchetti; Carla Maria Donzelli; Antonella Ravaggi; Franco E Odicino; Fabio Facchetti
Journal:  Virchows Arch       Date:  2016-04-08       Impact factor: 4.064

4.  An Alternate Diagnostic Algorithm for the Diagnosis of Intraepithelial Fallopian Tube Lesions.

Authors:  Marie E Perrone; Nicholas P Reder; Sergay N Agoff; Rochelle L Garcia; Kathy J Agnew; Barbara M Norquist; Kathryn P Pennington; Elizabeth M Swisher; Mark R Kilgore
Journal:  Int J Gynecol Pathol       Date:  2020-05       Impact factor: 2.762

5.  New views on the pathogenesis of high-grade pelvic serous carcinoma with suggestions for advancing future research.

Authors:  Mark E Sherman; Richard Guido; Nicolas Wentzensen; Hannah P Yang; Phuong L Mai; Mark H Greene
Journal:  Gynecol Oncol       Date:  2012-08-29       Impact factor: 5.482

6.  [The 2016 update of the S3 guideline for malignant tumours of the ovary : Role of pathology in diagnosis, therapy and clinical management of epithelial tumours].

Authors:  A Staebler; D Mayr
Journal:  Pathologe       Date:  2017-07       Impact factor: 1.011

Review 7.  Rationale for Developing a Specimen Bank to Study the Pathogenesis of High-Grade Serous Carcinoma: A Review of the Evidence.

Authors:  Mark E Sherman; Ronny I Drapkin; Neil S Horowitz; Christopher P Crum; Sue Friedman; Janice S Kwon; Douglas A Levine; Ie-Ming Shih; Donna Shoupe; Elizabeth M Swisher; Joan Walker; Britton Trabert; Mark H Greene; Goli Samimi; Sarah M Temkin; Lori M Minasian
Journal:  Cancer Prev Res (Phila)       Date:  2016-05-24

8.  Analysis of Telomere Lengths in p53 Signatures and Incidental Serous Tubal Intraepithelial Carcinomas Without Concurrent Ovarian Cancer.

Authors:  Shiho Asaka; Christine Davis; Shiou-Fu Lin; Tian-Li Wang; Christopher M Heaphy; Ie-Ming Shih
Journal:  Am J Surg Pathol       Date:  2019-08       Impact factor: 6.394

9.  Processing of fallopian tube, ovary, and endometrial surgical pathology specimens: A survey of U.S. laboratory practices.

Authors:  Goli Samimi; Britton Trabert; Máire A Duggan; Jennifer L Robinson; Kisha I Coa; Elizabeth Waibel; Edna Garcia; Lori M Minasian; Mark E Sherman
Journal:  Gynecol Oncol       Date:  2018-03       Impact factor: 5.482

Review 10.  Molecular-targeted therapies for ovarian cancer: prospects for the future.

Authors:  Tamotsu Sudo
Journal:  Int J Clin Oncol       Date:  2012-08-23       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.